Advertisement
Screener

PTC Therapeutics, Inc. (PTCT) Operating Lease, Weighted Average Discount Rate, Percent

2.8 / 5 stars · 68/120 Roast Me

PTC Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent

PTC Therapeutics, Inc. (PTCT) had Operating Lease, Weighted Average Discount Rate, Percent of 7.60% as of 2025-12-31, per its 10-K filed 2026-02-19.

Financial Statements › Notes › Leases

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-02-19

  • 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.60%.
  • 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 7.44%.
  • 2025-06-30: Operating Lease, Weighted Average Discount Rate, Percent 7.59%.
  • 2025-03-31: Operating Lease, Weighted Average Discount Rate, Percent 7.60%.
Period endOperating Lease, Weighted Average Discount Rate, Percent
2025-12-317.60%
10-K · filed 2026-02-19
2025-09-307.44%
10-Q · filed 2025-11-04
2025-06-307.59%
10-Q · filed 2025-08-07
2025-03-317.60%
10-Q · filed 2025-05-06
2024-12-317.64%
10-K · filed 2026-02-19
2024-09-308.06%
10-Q · filed 2024-11-07
2024-06-308.12%
10-Q · filed 2024-08-08
2024-03-318.75%
10-Q · filed 2024-04-25
2023-12-318.69%
10-K · filed 2025-02-27
2023-09-308.67%
10-Q · filed 2023-10-26
2023-06-308.65%
10-Q · filed 2023-08-03
2023-03-318.63%
10-Q · filed 2023-04-27
2022-12-318.61%
10-K · filed 2024-02-29
2022-09-308.64%
10-Q · filed 2022-10-27
2022-06-308.70%
10-Q · filed 2022-08-04
2022-03-318.91%
10-Q · filed 2022-05-03
2021-12-318.91%
10-K · filed 2023-02-21
2021-09-308.92%
10-Q · filed 2021-10-28
2021-06-308.90%
10-Q · filed 2021-07-29
2021-03-318.88%
10-Q · filed 2021-05-04
2020-12-318.86%
10-K · filed 2022-02-22
2020-09-308.64%
10-Q · filed 2020-10-29
2020-06-306.77%
10-Q · filed 2020-08-05
2020-03-317.34%
10-Q · filed 2020-04-30
2019-12-317.33%
10-K · filed 2021-02-25
2019-09-307.05%
10-Q · filed 2019-10-30
2019-06-307.18%
10-Q · filed 2019-08-06
2019-03-317.02%
10-Q · filed 2020-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Veradermics, Inc (MANE)United States$4.839B
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51